CHILDRENS CANCER GROUP

在这个赠款周期，费城儿童医院（CHOP）将继续其前30年的贡献CCG。 具体而言，CHOP将进入大量患者的治疗试验，努力提供患者样本用于生物和转化研究，开展机构和CCG相关的试点研究，并提供大量年轻和成熟的人才和科学领导力。在过去的周期中，CHOP的神经肿瘤学试点研究是4项CCG I期和II期研究的模板。 在这个周期中，神经肿瘤学项目将介绍新的递送途径，靶向治疗和1型神经纤维瘤病（NF-1）的探索，以探索遗传学和脑肿瘤的界面。与神经肿瘤学项目合作，神经母细胞瘤项目将开发TRK受体组用于诊断、预后和治疗。 基于CHOP试点研究，白血病小组将向CCG提出CNS复发和确定CNS疾病的延长、剂量降低的颅脊髓照射，并将引入骨髓复发的重复再诱导/再巩固策略。 CCG支持的CHOP白血病实验室研究包括治疗相关白血病和婴儿白血病的遗传流行病学以及小儿骨髓增生异常和骨髓增生综合征。 CHOP实体瘤组的间隔压缩的试点研究正在纳入下一个III期尤因试验。 t（2;13）和其他融合基因的PCR分析将用于检测微小残留病和开发靶向治疗。 肿瘤科新的实验治疗计划将研究独特的生物制剂，如HLA非依赖性TALL-104细胞系，TRK靶向CEP-751，IGFR可溶性受体和IGF 1受体反义。 CHOP的过渡方案旨在成为幸存者后续行动的原型，促进良好的预防保健战略和良好的研究。 第一个过渡研究旨在确定第二个恶性肿瘤患者的易感遗传风险因素。 CHOP和CCG的相互作用是双向的，对双方都是有益的。

In this grant cycle, The Children's Hospital of Philadelphia (CHOP) will continue its previous 30 years of contributions to CCG. Specifically, CHOP will enter large numbers of patients on therapeutic trials, diligently supply patient samples for biologic and translational studies, carry out both institutional and CCG-linked pilot studies, and provide a vast and varied repetoire of young and mature talent and scientific leadership. In the past cycle, CHOP's Neuro-Oncology pilot studies were templates for 4 CCG Phase I and Phase II studies. In this cycle the Neuro-Oncology Program will introduce novel routes of delivery, targetted therapy, and exploration of neurofibromatosis type 1(NF-1) to probe the interface of genetics and brain tumors. In collaboration with the Neuro-Oncology Program, the Neuroblastoma Program will develop the TRK group of receptors for diagnosis prognosis and therapy. Based on CHOP pilot studies, the Leukemia Group will propose to CCG protracted, reduced-dose craniospinal irradiation of CNS relapse and established CNS disease and will introduce the repetitive reinduction/reconsolidation strategy for marrow relapse. CCG- supported CHOP laboratory investigation in leukemia includes genetic epidemiology of treatment-related leukemias and infant leukemia and the pediatric myelodysplastic and myeloproliferative syndromes. The CHOP Solid Tumor Group's pilot study of interval compression is being incorporated into the next phase III Ewing's trial. PCR analysis of t(2;13) and other fusion genes will be used for detection of minimal residual disease and for development of targetted therapy. The Division of Oncology's new Experimental Therapeutics Program will investigate unique biologics such as the HLA independent TALL-104 cell line, TRK targetted CEP-751, and IGFR soluble receptor and antisense the IGF1 receptor. CHOPs Transition Program aims to be a prototype for follow-up of survivors, promoting good preventive health strategies and good research. The first transition study seeks to define predisposing genetic risk factors in patients who have second malignant neoplasms. The interactions of CHOP and CCG are bidirectional and are mutually rewarding for both.